FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2902527591> ?p ?o ?g. }

• W2902527591 endingPage "1749" @default.
• W2902527591 startingPage "1740" @default.
• W2902527591 abstract "The serotonergic system is a well-established modulator of l-dopa-induced dyskinesia. To date, targeting serotonin transporters or serotonin receptor subtype 1A (5-HT1A ) reduces l-dopa-induced dyskinesia in animal models; however, these strategies have failed to translate clinically. Ideally, a compound acting at both known antidyskinetic sites could optimize serotonin-mediated approaches. Vilazodone is a selective serotonin reuptake inhibitor and a partial 5-HT1A agonist approved by the U.S. Food and Drug Administration, situating Vilazodone in a unique position to reduce l-dopa-induced dyskinesia without compromising l-dopa-mediated motor improvements.The goal of the present study was to characterize Vilazodone's effects on l-dopa-induced behaviors, neurochemistry and gene expression in unilateral 6-hydroxydopamine-lesioned hemi-parkinsonian rats.In experiments 1 and 2, l-dopa-naïve and l-dopa-primed animals were coadministered Vilazodone and l-dopa daily for 3 weeks to model subchronic use, and behavioral, neurochemical, and messenger RNA (mRNA) expression changes were measured. In experiment 3, dyskinetic behavior was assessed following 5-HT1A or serotonin receptor subtype 1B blockade prior to Vilazodone-l-dopa coadministration.Vilazodone significantly suppressed developing and established l-dopa-induced dyskinesia without compromising the promotor effects of l-dopa therapy. In the dopamine-depleted striatum, Vilazodone-l-dopa cotreatment increased dopamine content, suggesting a normalization of dopamine kinetics in dyskinetic brain, and reduced l-dopa-induced c-Fos and preprodynorphin mRNA overexpression, indicative of attenuated dopamine D1 receptor-mediated direct pathway overactivity. Only 5-HT1A antagonism partially attenuated Vilazodone's antidyskinetic efficacy, suggesting both serotonin transporter-dependent effects and 5-HT1A receptors in Vilazodone's actions.Our findings show Vilazodone has a serotonin-dependent effect on rodent l-dopa-induced dyskinesia and implicate the potential for repositioning Vilazodone against l-dopa-induced dyskinesia development and expression in Parkinson's disease patients. © 2018 International Parkinson and Movement Disorder Society." @default.
• W2902527591 created "2018-12-11" @default.
• W2902527591 creator A5010041349 @default.
• W2902527591 creator A5022049336 @default.
• W2902527591 creator A5029519503 @default.
• W2902527591 creator A5036962830 @default.
• W2902527591 creator A5042196953 @default.
• W2902527591 creator A5052925145 @default.
• W2902527591 creator A5078687291 @default.
• W2902527591 creator A5080067336 @default.
• W2902527591 date "2018-11-01" @default.
• W2902527591 modified "2023-09-25" @default.
• W2902527591 title "Diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats" @default.
• W2902527591 cites W1596577698 @default.
• W2902527591 cites W1644067351 @default.
• W2902527591 cites W1778720383 @default.
• W2902527591 cites W1822924378 @default.
• W2902527591 cites W1926423117 @default.
• W2902527591 cites W1964978489 @default.
• W2902527591 cites W1981123646 @default.
• W2902527591 cites W1986694134 @default.
• W2902527591 cites W1991603311 @default.
• W2902527591 cites W1991955710 @default.
• W2902527591 cites W1997298496 @default.
• W2902527591 cites W1998175875 @default.
• W2902527591 cites W2008973569 @default.
• W2902527591 cites W2009081918 @default.
• W2902527591 cites W2019511637 @default.
• W2902527591 cites W2020263939 @default.
• W2902527591 cites W2023798224 @default.
• W2902527591 cites W2023942502 @default.
• W2902527591 cites W2035286056 @default.
• W2902527591 cites W2038472008 @default.
• W2902527591 cites W2044490788 @default.
• W2902527591 cites W2045697603 @default.
• W2902527591 cites W2057329581 @default.
• W2902527591 cites W2059237846 @default.
• W2902527591 cites W2061073038 @default.
• W2902527591 cites W2074112764 @default.
• W2902527591 cites W2076412877 @default.
• W2902527591 cites W2083577108 @default.
• W2902527591 cites W2098496103 @default.
• W2902527591 cites W2102668445 @default.
• W2902527591 cites W2106158259 @default.
• W2902527591 cites W2112559108 @default.
• W2902527591 cites W2112682964 @default.
• W2902527591 cites W2121103728 @default.
• W2902527591 cites W2123325665 @default.
• W2902527591 cites W2126401694 @default.
• W2902527591 cites W2146173262 @default.
• W2902527591 cites W2151685818 @default.
• W2902527591 cites W2157615852 @default.
• W2902527591 cites W2163546102 @default.
• W2902527591 cites W2170151780 @default.
• W2902527591 cites W2235481714 @default.
• W2902527591 cites W2285237309 @default.
• W2902527591 cites W2314410103 @default.
• W2902527591 cites W2480261859 @default.
• W2902527591 cites W2600577557 @default.
• W2902527591 cites W2747548337 @default.
• W2902527591 doi "https://doi.org/10.1002/mds.100" @default.
• W2902527591 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30485908" @default.
• W2902527591 hasPublicationYear "2018" @default.
• W2902527591 type Work @default.
• W2902527591 sameAs 2902527591 @default.
• W2902527591 citedByCount "18" @default.
• W2902527591 countsByYear W29025275912018 @default.
• W2902527591 countsByYear W29025275912019 @default.
• W2902527591 countsByYear W29025275912020 @default.
• W2902527591 countsByYear W29025275912021 @default.
• W2902527591 countsByYear W29025275912022 @default.
• W2902527591 countsByYear W29025275912023 @default.
• W2902527591 crossrefType "journal-article" @default.
• W2902527591 hasAuthorship W2902527591A5010041349 @default.
• W2902527591 hasAuthorship W2902527591A5022049336 @default.
• W2902527591 hasAuthorship W2902527591A5029519503 @default.
• W2902527591 hasAuthorship W2902527591A5036962830 @default.
• W2902527591 hasAuthorship W2902527591A5042196953 @default.
• W2902527591 hasAuthorship W2902527591A5052925145 @default.
• W2902527591 hasAuthorship W2902527591A5078687291 @default.
• W2902527591 hasAuthorship W2902527591A5080067336 @default.
• W2902527591 hasConcept C126322002 @default.
• W2902527591 hasConcept C137183658 @default.
• W2902527591 hasConcept C15744967 @default.
• W2902527591 hasConcept C169760540 @default.
• W2902527591 hasConcept C170493617 @default.
• W2902527591 hasConcept C25876315 @default.
• W2902527591 hasConcept C2775864247 @default.
• W2902527591 hasConcept C2776755682 @default.
• W2902527591 hasConcept C2778897192 @default.
• W2902527591 hasConcept C2779134260 @default.
• W2902527591 hasConcept C2779734285 @default.
• W2902527591 hasConcept C2780405171 @default.
• W2902527591 hasConcept C37000724 @default.
• W2902527591 hasConcept C513476851 @default.
• W2902527591 hasConcept C71924100 @default.
• W2902527591 hasConcept C98274493 @default.
• W2902527591 hasConceptScore W2902527591C126322002 @default.

• next